Cytovance, Vectron Partner on Complex Microbial Molecules

Cytovance Biologics partnered with Vectron Biosolutions to add customized E. coli strain development to its microbial program.

Leveraging Vectron’s vector engineering expression and secretion technology platforms, Cytovance will be able to offer customers more efficient options for E. coli-expressed products, with reduced downstream costs and processing time, and the full documentation of development work needed for regulatory approval. This aims to simplify and accelerate drug development efforts.

The partnership represents one of Vectron’s first business expansions into the U.S., following the company’s acquisition of T3S Technologies’ secretion platform in 2021. Vectron’s customers will also have the option to seamlessly transition their expressed protein to downstream development with Cytovance.

Vectron CEO and Co-founder, Trond Erik Vee Aune said, “We are very excited to partner with Cytovance Biologics to bring Vectron’s superior strain development services to customers in the USA. Cytovance’s position as a strong microbial CDMO is highly complementary to Vectron’s next-generation vector engineering technologies for microbial strain development, and together we will offer a complete package from gene to product, enabling customers to advance their proteins to the clinic and the market sooner and at lower cost.”

“As one of North America’s leading microbial manufacturing service providers, we are very excited to collaborate with the team at Vectron Biosolutions,” said Cytovance CCO, Axel Schleyer. “Their extensive expertise in gene expression for industrial protein production and our shared cultures of ingenuity, make them an excellent partner to support our customers looking to overcome large molecule obstacles and reach their clinical and commercial milestones,”